GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, has entered into an unsecured $1,000,000 Revolving Loan Agreement with Bowery Consulting Group Inc., according to a press release distributed via NEWMEDIAWIRE. The agreement, dated October 23, 2026, provides for advances of up to $1 million, subject to the lender's approval, carries interest at 12% per annum, and matures 12 months from issuance.
The financing comes with a significant governance shift. On the same day, Randal Chase, Dean Kollintzas, Nicole Lemerond, Jayne Morgan and John Spencer, Jr. resigned as directors, and Steven Brown, Tyler O'Brien and Manpreet Uppal were appointed to the board. Each new director was nominated by the lender pursuant to the loan agreement. The board now consists of five directors, and the company said it has determined that each of the newly appointed directors meets SEC and Nasdaq independence standards. O'Brien and Uppal will join the Audit Committee alongside Dr. Robert McNally.
David A. Dodd, Chairman and CEO of GeoVax, said securing the financing is an important achievement that reinforces the company's balance sheet and provides working capital to support operations. He welcomed the new directors, citing their diverse experience and leadership, and thanked the departing board members for their contributions. Dodd said the company believes it is entering a new chapter of growth, with a clear strategic path forward.
The loan matters because GeoVax is funding an ambitious clinical pipeline. Its priority program, GEO-MVA, is a Modified Vaccinia Ankara-based vaccine targeting mpox and smallpox that is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 trial in late 2026. In oncology, GeoVax is developing Gedeptin, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity, which has completed a Phase 1/2 trial in advanced head and neck cancer. The company maintains a global intellectual property portfolio and continues to evaluate strategic partnerships and funding opportunities. More information is available at www.geovax.com.
For investors and industry observers, the arrangement carries clear trade-offs. The 12% interest rate is steep for a clinical-stage borrower, and advances remain subject to the lender's sole discretion, meaning the full $1 million is not guaranteed. The lender's right to nominate three of five directors also gives Bowery Consulting Group substantial influence over GeoVax's strategy at a critical juncture. The company said further details will be contained in a Form 8-K to be filed with the Securities and Exchange Commission, and it cautioned that actual results may differ materially from forward-looking statements due to risks including trial outcomes, regulatory approvals, and its ability to raise capital or maintain Nasdaq compliance.
